NASDAQ:PRTA - Prothena Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.63 +0.06 (+0.52 %) (As of 12/11/2018 04:00 PM ET)Previous Close$11.57Today's Range$11.49 - $12.0052-Week Range$10.43 - $46.14Volume261,400 shsAverage Volume644,304 shsMarket Capitalization$452.85 millionP/E Ratio-2.86Dividend YieldN/ABeta2.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland. Receive PRTA News and Ratings via Email Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA Previous Symbol CUSIPN/A Webwww.prothena.com Phone011-353-1236-2500 Debt Debt-to-Equity RatioN/A Current Ratio19.34 Quick Ratio19.34 Price-To-Earnings Trailing P/E Ratio-2.86 Forward P/E Ratio-2.81 P/E GrowthN/A Sales & Book Value Annual Sales$27.52 million Price / Sales16.84 Cash FlowN/A Price / Cash FlowN/A Book Value$10.59 per share Price / Book1.10 Profitability EPS (Most Recent Fiscal Year)($4.07) Net Income$-153,230,000.00 Net Margins-18,276.97% Return on Equity-43.17% Return on Assets-29.80% Miscellaneous Employees125 Outstanding Shares39,860,000Market Cap$452.85 million OptionableOptionable Prothena (NASDAQ:PRTA) Frequently Asked Questions What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." How were Prothena's earnings last quarter? Prothena Co. PLC (NASDAQ:PRTA) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.43. The biotechnology company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million. Prothena had a negative return on equity of 43.17% and a negative net margin of 18,276.97%. View Prothena's Earnings History. When is Prothena's next earnings date? Prothena is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Prothena. What price target have analysts set for PRTA? 9 brokerages have issued twelve-month target prices for Prothena's shares. Their forecasts range from $12.00 to $87.00. On average, they anticipate Prothena's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 235.3% from the stock's current price. View Analyst Price Targets for Prothena. What is the consensus analysts' recommendation for Prothena? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena. What are Wall Street analysts saying about Prothena stock? Here are some recent quotes from research analysts about Prothena stock: 1. According to Zacks Investment Research, "Prothena’s wider-than-expected loss in the second quarter was disappointing. We expect investors’ focus to remain on pipeline updates as the company has no approved product in its portfolio yet. The license agreement with Roche for prasinezumab is big positive as it not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company also entered into an agreement with Celgene to develop its pipeline which should boost investor sentiment given the latter’s expertise. However, Prothena suffered a major setback with the discontinuation of development of lead candidate NEOD001. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Consequently, the company has decided to reduce its workforce by 57%. Shares have performed worse than the industry in the year so far." (8/10/2018) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $18. With discontinuation of NEOD001 development announced in April (our report here), investors are likely to focus on PRX002/RG7935 development as a treatment for Parkinson’s disease (PD). The company has guided to expectation for data from the Phase 2 PASADENA trial in 2020. Release of pharmacodynamic data from lower-dose cohorts of ATTR amyloidosis treatment PRX004 are anticipated in 2019." (8/8/2018) Has Prothena been receiving favorable news coverage? Press coverage about PRTA stock has trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Prothena earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Prothena's key competitors? Some companies that are related to Prothena include Zogenix (ZGNX), Innoviva (INVA), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK), Reata Pharmaceuticals (RETA), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), Cambrex (CBM), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE) and Esperion Therapeutics (ESPR). Who are Prothena's key executives? Prothena's management team includes the folowing people: Mr. Gene G. Kinney, Pres, CEO & Director (Age 49)Mr. Tran B. Nguyen, CFO & COO (Age 44)Mr. Arthur W. Homan, Chief Legal Officer (Age 59)Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 55)Dr. Wagner M. Zago, Chief Scientific Officer (Age 45) Who are Prothena's major shareholders? Prothena's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.66%), Scopia Capital Management LP (9.83%), BlackRock Inc. (8.31%), Dimensional Fund Advisors LP (2.37%), Vanguard Group Inc. (1.93%) and Pinnacle Associates Ltd. (0.60%). Company insiders that own Prothena stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena. Which institutional investors are selling Prothena stock? PRTA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Man Group plc, Pinnacle Associates Ltd., Virtus ETF Advisers LLC and Credit Suisse AG. View Insider Buying and Selling for Prothena. Which institutional investors are buying Prothena stock? PRTA stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Scopia Capital Management LP, Marshall Wace North America L.P., BlackRock Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Renaissance Technologies LLC and Paloma Partners Management Co. View Insider Buying and Selling for Prothena. How do I buy shares of Prothena? Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $11.63. How big of a company is Prothena? Prothena has a market capitalization of $452.85 million and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Prothena employs 125 workers across the globe. What is Prothena's official website? The official website for Prothena is http://www.prothena.com. How can I contact Prothena? Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected] MarketBeat Community Rating for Prothena (NASDAQ PRTA)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 392 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 635MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?